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Abstract
Background: The purpose of this randomised, single-centre study was to prospectively investigate the impact of
anaesthetic techniques for craniotomy on the release of cytokines IL-6, IL-8, IL-10, and to determine whether
intravenous anaesthesia compared to inhalational anaesthesia attenuates the inflammatory response.
Methods: The study enroled 40 patients undergoing craniotomy, allocated into two equal groups to receive either
sevoflurane (n = 20) or propofol (n = 20) in conjunction with remifentanil and rocuronium. The lungs were ventilated
mechanically to maintain normocapnia. Remifentanil infusion was adjusted according to the degree of surgical
manipulation and increased when mean arterial pressure and the heart rate increased by more than 30 % from
baseline. The depth of anaesthesia was adjusted to maintain a bispectral index (BIS) of 40–60. Invasive haemodynamic
monitoring was used. Serum levels of IL-6, IL-8 and IL-10 were measured before surgery and anaesthesia, during
tumour removal, at the end of surgery, and at 24 and 48 h after surgery. Postoperative complications (pain, vomiting,
changes in blood pressure, infection and pulmonary, cardiovascular and neurological events) were monitored during
the first 15 days after surgery.
Results: Compared with patients anaesthetised with sevoflurane, patients who received propofol had higher levels of
IL-10 (p = 0.0001) and lower IL-6/IL-10 concentration ratio during and at the end of surgery (p = 0.0001). Both groups
showed only a minor response of IL- 8 during and at the end of the surgery (p = 0.57).
Conclusions: Patients who received propofol had higher levels of IL-10 during surgery. Neither sevoflurane nor
propofol had any significant impact on the occurrence of postoperative complications. Our findings should incite
future studies to prove a potential medically important anti-inflammatory role of propofol in neuroanaesthesia.
Clinical trial registration: Identified as NCT02229201 at www.clinicaltrials.gov
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Background
Anaesthetic technique for craniotomy has to reduce stress
response to pain during intubation and surgical manipula-
tion. Emergence from anaesthesia has to be rapid and
smooth allowing early postoperative neurological evalu-
ation. Short-acting opioid remifentanil is commonly used
for neurosurgical procedures since it allows perfect titra-
tion of the analgesic effect to various noxious stimulation
intensities, along with rapid recovery and early
neurological evaluation [1–5]. The combination of remi-
fentanil and either propofol or sevoflurane has proved a
useful anaesthesia technique in elective neurosurgery
[6, 7]. A recent multicentre study revealed no difference
in early recovery between three groups of patients given
total intravenous anaesthesia (TIVA) with either propo-
fol-remifentanil, sevoflurane-remifentanil or sevoflurane-
fentanyl. Either technique provided optimal surgical condi-
tions [8].
Anaesthesia and surgery modulate complex immune
responses in patients undergoing major surgery [9]. There
is a delicate balance between the release of proinflamma-
tory (IL-6, IL-8) and anti-inflammatory (IL-10) cytokines.
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The cell-mediated immune response can increase the rate
of postoperative complications, such as infection, compro-
mised wound healing, cognitive impairment, and cancer
progression [9, 10]. An exaggerated proinflammatory re-
sponse, such as a systemic inflammatory response (SIRS)
may lead to haemodynamic decompensation and multi-
organ failure (MOF) [9–12]. Many studies have shown
that volatile anaesthetics reduce systemic and local inflam-
matory response during major surgery [11–14]. Animal
studies have demonstrated that volatile anaesthetics can
induce neuroinflammation, which leads to the decline of
cognitive function in rodents and possibly in humans
[15, 16]. Thus, we hypothesized that intravenous anaes-
thesia compared to inhalational anaesthesia attenuates
inflammatory response.
It is very important to prevent brain oedema and provide
optimal cerebral perfusion and oxygenation during neuro-
surgical procedures [1]. Optimal neuroprotective strategies
include appropriate patient positioning, management of
systemic and cerebral haemodynamics, maintenance of
fluid, electrolyte and coagulation balance, and postoper-
ative prevention and treatment of pain and postopera-
tive nausea and vomiting [1].
Our aim was to investigate the effect of anaesthetic
technique for craniotomy on the release of cytokines IL-6,
IL-8 and IL-10, and to determine whether intravenous
anaesthesia compared to inhalational anaesthesia atten-
uates the inflammatory response.
Methods
This prospective, randomised, double-blind single-centre
study was conducted at the Department of Anaesthesi-
ology and Surgical Intensive Therapy and at the De-
partment of Neurosurgery between 2010 and 2014. It
was carried out in close cooperation with the Institute
of Clinical Chemistry and Biochemistry, University
Medical Centre Ljubljana (trial registry: NCT02229201 at
www.clinicaltrials.gov). The study was approved by the
National Medical Ethics Committee of the Republic of
Slovenia. Written informed consent was obtained from all
participants. All the procedures were performed in ac-
cordance with the Helsinki declaration. The CONSORT
recommendations for reporting randomized trials were
followed.
We enrolled 40 ASA (American Society of Anaesthe-
siologists) physical status I-III cooperative patients aged
18–80 years with a GSC (Glasgow coma score) of 15
who were scheduled for elective craniotomy for an intra-
cerebral tumour. The patients included in the study were
operated on by the same surgeon and anaesthetised by
the same anaesthesiologist.
Patients were excluded if (a) they did not give written
informed consent, (b) they had an endocrine system dis-
ease, (c) they were taking drugs that alter endocrine
hormones (except dexamethasone that is invariably pre-
scribed to all patients with brain tumours at this depart-
ment), (d) they had a history of drug hypersensitivity, (e)
they had a history of drug addiction, or (f) they received
perioperative blood derivatives, such as red cell concen-
trates, platelet concentrates, fresh frozen plasma, cryopre-
cipitate, albumin, coagulation factors and immunoglobulins.
Using a computer-generated list the patients were
randomised to either group by the third author IP, who
was not involved in patient care. The first author (JMB)
enrolled the patients and informed them about the par-
ticipation in the study. The surgeon and the anaesthesi-
ologist were blinded to the type of anaesthesia used.
All patients were on intravenous dexamethasone 4 ×
4 mg/day-1 with the first dose given at least 1 day prior
to surgery.
In the operating room standard monitoring was insti-
tuted. An arterial catheter was placed in the radial artery
for continuous blood pressure monitoring. Advanced pulse
contour cardiac output monitoring using the Vigileo/
FloTrac device (Edwards Lifescience, CA, USA) was applied.
Patients were premedicated with midazolam (2-3 mg i.v.)
and ondansetron (4–8 mg i.v.). Antibiotic prophylaxis
with intravenous cefazolin 2 g/100 ml – 0.9 % NaCl was
invariably used in all patients.
In propofol group anaesthesia was induced with pro-
pofol 1-2 mgkg-1 (Propoven, Fresenius Kabi AG, Bad
Homburg, Germany) and in sevoflurane group with 6 %
sevoflurane using a deep breath technique Sevorane,
Abbott Laboratories, Texas, USA). Before intubation
all patients received remifentanil 0.5–1 μgkg-1 (Ultiva,
GlaxoSmithKline) and rocuronium 0.6 mgkg-1 (Esmeron,
MSD, NY, USA).
After intubation both groups were ventilated mechan-
ically with oxygen-air mixtures and with an I/E ratio of
1:2. The respiratory rate was adjusted to maintain normal
values of paCO2 (partial pressure of carbon dioxide in ar-
terial blood). The tidal volume was set to 8 mlkg-1. The
peak inspiratory pressure was limited to 35 cm H2O. The
fraction of inspired oxygen was adjusted to maintain nor-
mal values of partial pressure of oxygen in arterial blood.
Anaesthesia was maintained by continuous infusion of
propofol 4–6 mg kg-1h-1 in the propofol group and with
sevoflurane 0.8–1 MAC in the sevoflurane group. Remi-
fentanil was adjusted according to the degree of surgical
manipulation (0.1–2 μg kg-1min-1) and increased when
mean arterial pressure and heart rate increased by more
than 30 % from baseline. The depth of anaesthesia was
measured by the bispectral index (BIS) and the values
were maintained at 40–60.
The following algorithm was used for haemo-
dynamic management: intraoperative basal fluid re-
placement was realized with continuous infusion of
0.9 % NaCl 8 ml-1kg-1h-1 for the first hour, followed
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by 2.5 ml-1kg-1h-1. Additional boluses of 3 ml -1kg-1 of col-
loid solution (Voluven 130/0.4 6 %; Fresenius Kabi AG,
Bad Homburg, Germany) were given when stroke volume
variation (SVV) measured by Vigileo/FloTrac system rose
above 10 % (a sustained change during the previous
5 min) or in the case of a positive response (cardiac index
[CI] increase above 10 %) to previous fluid challenge). If
there was no improvement after fluid bolus, ephedrine
(0.5 % Ephedrine, UMC Ljubljana Pharmacy, Slovenia) 5–
10 mg (0.01 %, UMC Ljubljana Pharmacy, Slovenia) was
instituted to maintain CI between 2 to 3.5 Lmin-1m-2.
If CI > 2 Lmin-1m-2, SVV < 10 % and mean arterial
pressure < 60 mmHg, phenylephrine 50–100 μg was given.
If CI < 2 Lmin-1m-2, SVV < 10 % and heart beat < 40 min-1,
atropine 0.5 mg was given. If mean arterial pressure in-
creased by more than 30 % and heart rate by more than
30 % from baseline, the infusion of remifentanil was in-
creased by 0.1 μg kg-1min-1. Any adverse haemodynamic
events (an increase in mean arterial pressure of more than
30 % and/or in heart rate of more than 30 % from
baseline) that did not respond to higher remifentanil
infusion rate, were managed with urapidil or meto-
prolol, as appropriate. Blood loss was managed with
colloids (Voluven 130/0.4 6 %; Fresenius Kabi AG,
Bad Homburg, Germany) until a reduced PRBC trans-
fusion trigger (haemoglobin level < 100 gl-1) was
reached. Haemodynamic parameters were recorded
continuously at 5-min intervals from the beginning of
induction to discharge from the postanaesthesia care
unit (PACU). During closing of the dura the patients
were given a bolus dose of piritramide 0.1 mg/kg-1
(Dipidolor, Janssen-Cillag GmbH, Neuss, Germany).
We stopped sevoflurane and propofol infusion at the
the last skin suture; remifentanil infusion was stopped
after the removal of the Mayfield head holder.
Postoperatively patient-controlled analgesia (PCA) with
continuous intravenous infusion of piritramide was started.
The duration of the operation was defined as the time from
the application of the Mayfield head holder to its removal.
The duration of anaesthesia was defined as the time from
induction to extubation. The time from the discontinu-
ation of anaesthetics to tracheal extubation was also re-
corded. All the patients were extubated in the operating
theatre and then transferred to the PACU.
The patients stayed in the PACU for not more than
2 h and were then taken to the intensive care unit (ICU)
of the Department of Neurosurgery.
Standard postoperative monitoring generally used in
these procedures was implemented. Oxygen was admin-
istered via a Venturi mask and titrated to the lowest level
needed to achieve arterial oxygen saturation greater than
96 %. During the hospital stay the main investigator
(JMB) visited the patients daily to check the adverse
events and the given medication.
Measurements
The data recorded included demographics, duration of
surgery and anaesthesia, the consumption of intraopera-
tive drugs, fluid balance, emergence and haemodynamic
parameters. Postoperative complications were monitored
during 15 days after surgery.
Postoperative complications were defined as any unin-
tended changes in body function or well-being, such as
hypertension (systolic blood pressure 30 % higher than
the baseline level), postoperative nausea with vomiting,
pain (visual analogue scale (VAS) > 3), infection, pul-
monary, cardiovascular and neurological events, reoper-
ation and death. The length of hospital stay was also
recorded.
Serum levels of IL-6, IL-8 and IL-10 were measured in
the pre-, peri- and postoperative periods. Arterial blood
samples for determinations of cytokines IL-6, IL-8 and
IL-10 were drawn at the following time points: (1) before
induction, (2) during tumour resection, (3) at the end of
surgery, (4) 24 h after surgery, and (5) 48 h after surgery.
For the analysis of serum IL-6, IL-8 and IL-10 blood
samples were collected in tubes with no additive. After
centrifugation serum samples were stored at –20 °C until
analysis. The samples were analysed in a single batch.
Chemiluminescent immunometric assay (Immulite analyzer;
Siemens Healthcare, Erlangen, Germany) was used to
measure the concentrations of IL-6, IL-8, and IL-10.
The primary outcome measures were serum levels of
IL-6, IL-8 and IL-10.
The secondary outcome measures included the length
of hospital stay and postoperative complications.
Statistical analysis
The sample size was calculated from the previous pilot
study of two independent groups (5 patients received pro-
pofol and 5 patients received sevoflurane) using a priori
two tailed t-test power analysis. The difference in median
serum concentration ratios (IL-10i/IL-10i=1) for each
blood draw time point (i = 2, 3, 4, 5) against baseline
IL-101 concentration (before surgery and anaesthesia)
was used for the effect size calculation and the resulting
minimum sample size determination. For a significance
level of 5 % (α = 0.05) and a power of 80 % (β = 0.2) the
calculated minimum sample size was 19. To compen-
sate for possible withdrawals, 20 patients were included
into each group.
The two-tailed t-test with unequal variances or the
Chi-square test were used to test the differences in demo-
graphic data, duration of the procedure and anaesthesia,
drug consumption, fluid balance, postoperative complica-
tions, haemodynamic parameters and hospital stay. The
exact Mann-Whitney U-test was used to compare the
differences in IL-6i/IL-61, IL-8i/IL-81 and IL-10i/IL-101
median ratio values and the changes in mean arterial
Markovic-Bozic et al. BMC Anesthesiology  (2016) 16:18 Page 3 of 8
pressure (MAP) and cardiac output (CO) during sur-
gery between the groups.
The medians and the means of continuous variables
are presented, and categorical data are summarized as
counts. A p-value of less than 0.05 was considered sta-
tistically significant. Data were analysed by SPSS 13.0
software package.
Results
The study included 40 patients, 20 in the propofol group
and 20 in the sevoflurane group (Fig. 1). None of the pa-
tients had signs of preoperative infection. All patients
underwent craniotomy because of intracerebral tumour.
Thirty-eight patients were operated on for the first time
for the underlying pathology and 2 patients were reoper-
ated. There were 37 supratentorial and and 3 infraten-
torial tumours (2 in the propofol group and 1 in the
sevoflurane group). No significant differences were found
between the groups regarding their demographics, under-
lying pathology and position during surgery (Table 1).
Neither were there any significant differences in the
length of hospital stay and intraoperative and postoper-
ative variables that could have influenced the inflamma-
tory response (Table 2). Patients who received propofol
showed statistically significant increase in plasma IL-10
levels from baseline during surgery that lasted for 24 h
after surgery (p = 0.0001) (Fig. 2b).
Patients in sevoflurane and propofol groups showed
comparable perioperative changes in plasma levels of
IL-6 (Fig. 2a), and IL-8 (Fig. 2d) at all time points. Pa-
tients who received propofol showed statistically signifi-
cant decrease in IL-6/IL-10 ratio during surgery that
lasted until the end of surgery (p = 0.0001) (Fig. 2c).
The difference in mean arterial pressure (MAP) and
cardiac output (CO) during surgery was not statistically
significant between the groups (Fig. 3).
Discussion
Our study of patients undergoing craniotomy for intrace-
rebral tumours showed that propofol based anaesthesia
was associated with significantly higher anti-inflammatory
cytokine IL-10 levels than anaesthesia with sevoflurane,
indicating that propofol anaesthesia may produce neuro-
protective effects despite comparable neurological out-
comes, length of hospital stay, and 15-day mortality rates
of both groups.
Cytokines are a group of important inflammatory me-
diators that act in cascades, inducing or inhibiting each
other [17]. They can enter the brain in many ways: they
can cross the blood brain barrier (BBB) or bind to
Fig. 1 Flow diagram of the study
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receptors associated with peripheral afferent nerves as
part of the vagus nerve. They are produced in the CNS
by activated microglia that have migrated as phagocytes,
as well as by astrocytes and neurons [18, 19].
Finally, cortisol passes the blood brain barrier and influ-
ences the immune system in the CNS and peripheral ner-
vous system [20]. In the present study we did not measure
changes in cortisol levels. Citerio et al. showed, however, that
during elective craniotomy intravenous anaesthesia was asso-
ciated with a significant attenuation of neuroendocrine
stress response [8]. A significant decrease in immune cell
populations was found after intravenous induction in pa-
tients undergoing craniotomy [12].
Propofol reduces production of proinflammatory cyto-
kines, alters expression of nitric oxide, and inhibits neutro-
phil function [21]. A recent in-vitro study showed that
propofol almost completely inhibits lipopolysaccharide-
induced activation of microglia and the production of proin-
flammatory cytokines [22]. It has been shown to attenuate
neutrophil-mediated inflammatory diseases by blocking for-
myl peptide receptor 1 (FPR1) [23].
Our results suggest that TIVA with propofol exerts anti-
inflammatory effects during and at the end of craniotomy,
as reflected by a statistically significant decrease in IL-6/IL-
10 ratio. These effects, however, seem to be only temporary,
as IL-10 levels returned to baseline values on the first and
second postoperative days. Sevoflurane had no major im-
pact on IL-10 levels during either preoperative, periopera-
tive or postoperative periods. In the postoperative period
both anaesthestics showed proinflammatory action, as dem-
onstrated by increased IL-6 levels, but the difference be-
tween the groups was not statistically significant. Neither
anaesthetic had any major impact on the rate of postopera-
tive complications. This finding suggests a potential medic-
ally important anti-inflammatory influence of propofol,
which, however, should be confirmed by further studies.
Meta-analysis of several studies comparing propofol and
volatile agents used for anaesthesia during elective craniot-
omy revealed no significant difference between both anaes-
thetic techniques in the majority of the measured outcomes
[24]. According to Tange et al, who found increased
Table 1 Baseline demographics and surgical procedure
S P
N (number) 20 20
Age (years) 54 ± 14 53 ± 16
Weight (kg) 76 ± 12 79 ± 14
Gender (M/F) 6/14 10/10











Duration of procedure (min) 163 ± 43 161 ± 68
Duration of anaesthesia (min) 182 ± 41 192 ± 71
The results are expressed as mean ± SD or number of patients
The differences between groups were not significant (p > 0.05)
Abbreviations: ASA American Society of Anaesthesiologists
Table 2 Intraoperative variables and postoperative complications
S P
Propofol (mg) 1060 ± 379
Remifentanil (mg) 11 ± 4 14 ± 9
Total loss of blood (ml) 405 ± 267 325 ± 226
Crystalloids (ml) 1065 ± 391 1176 ± 535
Colloids (ml) 441 ± 370 462 ± 327
Urine volume (ml) 750 ± 477 537 ± 440
Efedrin (mg) 7 ± 6 4 ± 6
Phenylephrine(mcg) 15 ± 37 30 ± 66
Intraoperative hypotension 5 4
Time to extubation (min) 9 ± 4 10 ± 3
Vomiting in PACU (yes/no) 7/13 3/17
VAS >3 in PACU (yes/no) 17/3 14/6
Additional piritramide (mg) 6 ± 4 4 ± 3
Postoperative hypertension 4 5
Vomiting in ICU (yes/no) 9/11 7/13
VAS >3 in ICU (yes/no) 1/19 0/20
Hospital stay (days) 12 ± 11 12 ± 8
Death 0 0
Reoperation 0 1




(pulmonary embolism/other) 1/0 1/0
Infections (wound infection/other) 1/0 1/0




Balance disorder 1 2
Deafness or loss of smell 2 1
Confusion 1 0
Cerebrovascular insult 1 0
The results are expressed as mean ± SD or number of patients
The differences between groups were not significant (p > 0.05)
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cerebrospinal fluid levels of IL6 in the sevoflurane group,
differences in neuroinflammatory response may be attrib-
uted to different anaesthetic techniques used [25].
In our study the sevoflurane and the propofol groups
showed practically equal minor changes in IL-8 concen-
trations during and after surgery. The same results were
found in patients undergoing craniotomy under general
anaesthesia and those undergoing awake craniotomy [26].
IL-8 is an important proinflammatory inteleukin that may
contribute to psychiatric complications of surgery [27].
Deviations of cytokine concentrations from the normal
may be attributed to the effects of pre-existing medical ill-
ness, treatment modality, type of surgery or postoperative
complications [18]. During neurosurgery neuroinflammation
is caused by brain injury that is induced by various factors
(brain tissue and vasculature manipulation, global haemo-
dynamic changes) and affects normal brain structures [1].
Appropriate management of systemic and cerebral
haemodynamic variables (cardiac output, arterial blood
pressure, cardiac rhythm, cerebral blood flow) is a corner-
stone of neuroanaesthesia [1]. In our study there were no
significant differences in the degree of haemodynamic
stability between the two groups (Fig. 3).
Corticosteroids are usually indicated in any brain tumour
patient with symptomatic peritumoral oedema [28, 29].
Dexamethasone is generally used as it has relatively little
mineralocorticoid activity, and is possibly associated with a
lower risk of infection and cognitive impairment than other
corticosteroids [28, 29]. At the Ljubljana Department of
Neurosurgery a regimen with dexamethasone is invariably
prescribed to all patients with brain tumours. This policy
consitutes an inevitable limitation to our study as the impact
of dexamethasone on the inflammatory system is well-
known [28–30]. In their study, El Azab et al observed
Fig. 2 The ratios of IL-6i, IL-10i, (IL-6/IL-10)i and IL-8i to baseline values IL-61, IL-101, (IL-6/IL-10)1 and IL-81 at various blood-sample draw time.
Measurements (i): (1) before surgery and anaesthesia (2) during surgery, (3) at the end of surgery, (4) on the first postoperative day, (5) on the
second postoperative day. The data are presented as the median values in all studied patients. a IL-6i/IL-61 concentration ratio was not significantly
different at any blood-sample draw time (measurement 2, p = 0.23; measurement 3, p = 0.12; measurement 4, p = 0.40; measurement 5,
p = 0.55). b IL-10i/IL-101 concentration ratio significantly increased in the propofol group at measurements 2 and 3 (measurement 2, p = 0.0001;
measurement 3, p < 0.0001; measurement 4, p = 0.14; measurement 5, p = 0.38). c The (IL-6/IL-10)i/ (IL-6/IL-10)1 ratio in the propofol group
significantly decreased at measurements 2 and 3 (measurement 2, p = 0.0001; measurement 3, p < 0.0001; measurement 4, p = 0.08; measurement 5,
p = 0.29). d IL-8i/IL-81 concentration ratio was not significantly different at any blood-sample draw time (measurement 2, p = 0.57; measurement 3,
p = 0.67; measurement 4, p = 0.15; measurement 5, p = 0.43)
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elevated IL -10 levels and decreased IL-6 and IL-8 levels in
patients given dexamethasone in comparison to controls
[30]. All patients included in our study were on the same
dexamethasone regimen of 4 × 4 mg/day-1 for the same
period of time before and after surgery. Because both
groups were treated with dexamethasone according to
the same protocol, we believe that the difference in
cytokine profile changes is attributable to different an-
aesthetic techniques used.
Pain is another factor enhancing systemic inflamma-
tory response and increasing serum cytokine levels [31].
In our study, possible impact of pain-related stress on the
inflammatory response can be excluded. The difference in
the amount of intraoperative remifentanil between the
groups was not significant. The differences in VAS scores
and requirements for additional analgesia with piritramide
between the groups were not significant (Table 2).
The major advantage of our study is that the observa-
tion period was extended to 48 h postoperatively. Post-
operative results failed to show clinical advantage of one
anaesthetic technique over the other. However, we did
not assess postoperative cognitive functions, long-term
neurological morbidity and mortality, and quality of life.
A longer observation period would be needed to clarify
possible long-lasting effects of anaesthetics on neuroin-
flammation after craniotomy for intracerebral tumours.
Conclusions
In conclusion, significant differences in cytokine profiles
were found between the two anaesthesia groups. With pro-
pofol anaesthesia the concentration of anti-inflammatory
cytokine IL-10 significantly increased during surgery. These
findings, however, seem to have little effect on outcome,
since neither sevoflurane nor propofol had any significant
impact on the occurrence of postoperative complications.
Our findings should incite future studies to prove potential
medically important anti-inflammatory effects of propofol
in neuroanaesthesia.
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